LaVeen continuous peritoneal-jugular shunt. Improvement of renal function in ascitic patients.
30 consecutive patients with cirrhosis of the liver complicated by refractory ascites, hepatorenal syndrome, or both, received a LeVeen peritoneal-venous shunt. After surgery, these patients demonstrated a decreased abdominal girth (108 vs 93 cm, P less than .001), decreased body weight (80 vs 70 kg, P less than .001), and increased urinary flow (607 vs 4,254 ml, P less than .001). All patients had previously failed to show substantial benefit with 7 to 124 days of medical care. The mean BUN value was significantly decreased, from 39 to 23 mg/100 ml (P less than .005). Adosterone retention was reduced from a mean value of 32 to 12.8 ng/100 ml. The LeVeen continuous peritoneal-venous shunt is an important innovation that completely relieves refractory ascites in cirrhotic patients and reverses the pathophysiology of the hepatorenal syndrome.
D000005:Abdomen / Q000473:pathology; D000450:Aldosterone / Q000097:blood; D001806:Blood Urea Nitrogen; D001835:Body Weight; D003404:Creatinine / Q000097:blood; D006801:Humans; D007601:Jugular Veins / Q000601:surgery*; D007668:Kidney / Q000503:physiopathology*; D008103:Liver Cirrhosis / Q000401:mortality / Q000601:surgery*; D010529:Peritoneal Cavity / Q000601:surgery*; D014556:Urine
D000450:Aldosterone; D003404:Creatinine